BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Recommendation of “Buy” from Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have earned an average recommendation of “Buy” from the six analysts that are currently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $13.83.

Separately, Needham & Company LLC restated a “buy” rating and set a $12.00 target price on shares of BioCryst Pharmaceuticals in a report on Wednesday, April 10th.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ BCRX opened at $4.27 on Tuesday. The company’s 50 day simple moving average is $5.07 and its 200 day simple moving average is $5.52. BioCryst Pharmaceuticals has a fifty-two week low of $4.03 and a fifty-two week high of $9.06. The firm has a market capitalization of $881.03 million, a P/E ratio of -3.62 and a beta of 1.90.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Monday, February 26th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). The firm had revenue of $93.40 million during the quarter, compared to the consensus estimate of $89.19 million. Sell-side analysts expect that BioCryst Pharmaceuticals will post -0.69 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Fifth Third Bancorp increased its holdings in shares of BioCryst Pharmaceuticals by 17,500.0% in the third quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 3,500 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in BioCryst Pharmaceuticals by 96.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 2,388 shares in the last quarter. Quarry LP acquired a new stake in BioCryst Pharmaceuticals during the 4th quarter worth approximately $54,000. Tower Research Capital LLC TRC lifted its stake in BioCryst Pharmaceuticals by 131.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 10,420 shares of the biotechnology company’s stock valued at $62,000 after buying an additional 5,912 shares in the last quarter. Finally, JGP Global Gestao de Recursos Ltda. acquired a new position in shares of BioCryst Pharmaceuticals in the fourth quarter valued at approximately $64,000. 85.88% of the stock is currently owned by institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.